The therapeutic efficacy of conjugated linoleic acid - Paclitaxel on glioma in the rat

Biomaterials

Volumn 31, Issue 22, 2010, Pages 5855-5864

  Ke, Xi Yu ^a   Zhao, Bo Jun ^a   Zhao, Xin ^a   Wang, Ying ^a   Huang, Yue ^a   Chen, Xiao Mei ^a   Zhao, Bing Xiang ^a   Zhao, Shan Shan ^a   Zhang, Xuan ^a   Zhang, Qiang ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Anti tumor efficacy; Blood brain barrier; Brain glioma bearing rats; Conjugate; Conjugated linoleic acid (CLA); Paclitaxel (PTX)

Indexed keywords

ANTI-TUMOR ACTIVITIES; ANTI-TUMOR EFFICACY; ANTI-TUMORS; ANTICANCER DRUG; BLOOD-BRAIN BARRIER; BRAIN TISSUE; BRAIN TUMORS; CELL-CYCLE PROGRESSION; CELLULAR UPTAKE EFFICIENCY; CHEMOTHERAPEUTIC AGENTS; CONJUGATED LINOLEIC ACID; GLIOMA CELLS; IN-VITRO; MICROTUBULE ASSEMBLY; PACLITAXEL; POTENTIAL ACTIVITIES; PRODRUGS; RAT PLASMA; THERAPEUTIC EFFICACY;

ACIDS; BEARINGS (STRUCTURAL); BLOOD; DRUG PRODUCTS; FATTY ACIDS; PHARMACOKINETICS; RATS; TUMORS;

BRAIN;

CONJUGATED LINOLEIC ACID; PACLITAXEL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN TUMOR; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CHEMICAL STRUCTURE; CONTROLLED STUDY; COVALENT BOND; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG STRUCTURE; DRUG SYNTHESIS; GLIOMA; HYDROLYSIS; IN VITRO STUDY; MALE; MEAN RESIDENCE TIME; MICROTUBULE ASSEMBLY; MOLECULAR WEIGHT; MOUSE; NONHUMAN; POLYMERIZATION; PRIORITY JOURNAL; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BRAIN; BRAIN NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; GLIOMA; LINOLEIC ACIDS, CONJUGATED; MALE; PACLITAXEL; RATS; RATS, SPRAGUE-DAWLEY; TUBULIN;

RATTUS;

EID: 77953081486     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2010.03.079     Document Type: Article

References (48)

1. Sauer L.A., Blask D.E., Dauchy R.T. Dietary factors and growth and metabolism in experimental tumors. J Nutr Biochem 2007, 18(10):637-649.
2. Cunningham D.C., Harrison L.Y., Shultz T.D. Proliferative responses of normal human mammary and MCF-7 breast cancer cells to linoleic acid, conjugated linoleic acid and eicosanoid synthesis inhibitors in culture. Anticancer Res 1997, 17(1A):197-203.
3. Maggiora M., Bologna M., Cerù M.P., Possati L., Angelucci A., Cimini A., et al. An overview of the effect of linoleic and conjugated-linoleic acids on the growth of several human tumor cell lines. Int J Cancer 2004, 112(6):909-919.
4. Tanmahasamut P., Liu J., Hendry L.B., Sidell N. Conjugated linoleic acid blocks estrogen signaling in human breast cancer cells. J Nutr 2004, 134(3):674-680.
5. Kelley N.S., Hubbard N.E., Erickson K.L. Conjugated linoleic acid isomers and cancer. J Nutr 2007, 137(12):2599-2607.
6. Masso-Welch P.A., Zangani D., Ip C., Vaughan M.M., Shoemaker S., Ramirez R.A., et al. Inhibition of angiogenesis by the cancer chemopreventive agent conjugated linoleic acid. Cancer Res 2002, 62(15):4383-4389.
7. Masso-Welch P.A., Zangani D., Ip C., Vaughan M.M., Shoemaker S.F., McGee S.O., et al. Isomers of conjugated linoleic acid differ in their effects on angiogenesis and survival of mouse mammary adipose vasculature. J Nutr 2004, 134(2):299-307.
8. Wang L.S., Huang Y.W., Sugimoto Y., Liu S., Chang H.L., Ye W., et al. Effects of human breast stromal cells on conjugated linoleic acid (CLA) modulated vascular endothelial growth factor-A (VEGF-A) expression in MCF-7 cells. Anticancer Res 2005, 25(6B):4061-4068.
9. Moon E.J., Lee Y.M., Kim K.W. Anti-angiogenic activity of conjugated linoleic acid on basic fibroblast growth factor-induced angiogenesis. Oncol Rep 2003, 10(3):617-621.
10. Ip M.M., Masso-Welch P.A., Ip C. Prevention of mammary cancer with conjugated linoleic acid: role of the stroma and the epithelium. J Mammary Gland Biol Neoplasia 2003, 8(1):103-118.
11. Holland E.C. Progenitor cells and glioma formation. Curr Opin Neurol 2001, 14(6):683-688.
12. Parker J.N., Bauer D.F., Cody J.J., Markert J.M. Oncolytic viral therapy of malignant glioma. Neurotherapeutics 2009, 6(3):558-569.
13. Xie J., Marijnissen J.C., Wang C.H. Microparticles developed by electrohydrodynamic atomization for the local delivery of anticancer drug to treat C6 glioma in vitro. Biomaterials 2006, 27(17):3321-3332.
14. Cimini A., Cristiano L., Colafarina S., Benedetti E., Di Loreto S., Festuccia C., et al. PPARgamma-dependent effects of conjugated linoleic acid on the human glioblastoma cell line (ADF). Int J Cancer 2005, 117(6):923-933.
15. Sikorski A.M., Hebert N., Swain R.A. Conjugated Linoleic Acid (CLA) inhibits new vessel growth in the mammalian brain. Brain Res 2008, 1213:35-40.
16. Koo Y.E., Reddy G.R., Bhojani M., Schneider R., Philbert M.A., Rehemtulla A., et al. Brain cancer diagnosis and therapy with nanoplatforms. Adv Drug Deliv Rev 2006, 58(14):1556-1577.
17. Pardridge W.M. BBB-Genomics: creating new openings for brain-drug targeting. Drug Discov Today 2001, 6(8):381-383.
18. Fa M., Diana A., Carta G., Cordeddu L., Melis M.P., Murru E., et al. Incorporation and metabolism of c9, t11 and t10, c12 conjugated linoleic acid (CLA) isomers in rat brain. Biochim Biophys Acta 2005, 1736(1):61-66.
19. Perioli L., Ambrogi V., Bernardini C., Grandolini G., Ricci M., Giovagnoli S., et al. Potential prodrugs of non-steroidal anti-inflammatory agents for targeted drug delivery to the CNS. Eur J Med Chem 2004, 39(8):715-727.
20. Rowinsky E.K., Cazenave L.A., Donehower R.C. Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst 1990, 82(15):1247-1259.
21. Brouwer E., Verweij J., De Bruijn P., Loos W.J., Pillay M., Buijs D., et al. Measurement of fraction unbound paclitaxel in human plasma. Drug Metab Dispos 2000, 28(10):1141-1145.
22. Belotti D., Vergani V., Drudis T., Borsotti P., Pitelli M.R., Viale G., et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 1996, 2(11):1843-1849.
23. Chen J.G., Yang C.P., Cammer M., Horwitz S.B. Gene expression and mitotic exit induced by microtubule-stabilizing drugs. Cancer Res 2003, 63(22):7891-7899.
24. Sparreboom A., van Tellingen O., Nooijen W.J., Beijnen J.H. Tissue distribution, metabolism and excretion of paclitaxel in mice. Anticancer Drugs 1996, 7(1):78-86.
25. Gallo J.M., Li S., Guo P., Reed K., Ma J. The effect of P-glycoprotein on paclitaxel brain and brain tumor distribution in mice. Cancer Res 2003, 63(16):5114-5117.
26. Menéndez J.A., del Mar Barbacid M., Montero S., Sevilla E., Escrich E., Solanas M., et al. Effects of gamma-linolenic acid and oleic acid on paclitaxel cytotoxicity in human breast cancer cells. Eur J Cancer 2001, 37(3):402-413.
27. Fite A., Goua M., Wahle K.W., Schofield A.C., Hutcheon A.W., Heys S.D. Potentiation of the anti-tumour effect of docetaxel by conjugated linoleic acids (CLAs) in breast cancer cells in vitro. Prostaglandins Leukot Essent Fatty Acids 2007, 77(2):87-96.
28. Guo D.D., Moon H.S., Arote R., Seo J.H., Quan J.S., Choi Y.J., et al. Enhanced anticancer effect of conjugated linoleic acid by conjugation with Pluronic F127 on MCF-7 breast cancer cells. Cancer Lett 2007, 254(2):244-254.
29. Guo D.D., Xu C.X., Quan J.S., Song C.K., Jin H., Kim D.D., et al. Synergistic anti-tumor activity of paclitaxel-incorporated conjugated linoleic acid-coupled poloxamer thermosensitive hydrogel in vitro and in vivo. Biomaterials 2009, 30(27):4777-4785.
30. Bradley M.O., Webb N.L., Anthony F.H., Devanesan P., Witman P.A., Hemamalini S., et al. Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel. Clin Cancer Res 2001, 7(10):3229-3238.
31. Wolff A.C., Donehower R.C., Carducci M.K., Carducci M.A., Brahmer J.R., Zabelina Y., et al. Phase I study of docosahexaenoic acid-paclitaxel: a taxane-fatty acid conjugate with a unique pharmacology and toxicity profile. Clin Cancer Res 2003, 9(10 Pt 1):3589-3597.
32. Fracasso P.M., Picus J., Wildi J.D., Goodner S.A., Creekmore A.N., Gao F., et al. Phase 1 and pharmacokinetic study of weekly docosahexaenoic acid-paclitaxel, Taxoprexin, in resistant solid tumor malignancies. Cancer Chemother Pharmacol 2009, 63(3):451-458.
33. Hatta S., Ozawa H., Saito T., Amemiya N., Ohshika H. Tubulin stimulates adenylyl cyclase activity in rat striatal membranes via transfer of guanine nucleotide to Gs protein. Brain Res 1995, 704(1):23-30.
34. Schiff P.B., Fant J., Horwitz S.B. Promotion of microtubule assembly in vitro by taxol. Nature 1979, 277(5698):665-667.
35. Shelanski M.L., Gaskin F., Cantor C.R. Microtubule assembly in the absence of added nucleotides. Proc Natl Acad Sci USA 1973, 70(3):765-768.
36. Yang T., Choi M.K., Cui F.D., Kim J.S., Chung S.J., Shim C.K., et al. Preparation and evaluation of paclitaxel-loaded PEGylated immunoliposome. J Control Release 2007, 120(3):169-177.
37. Vichai V., Kirtikara K. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc 2006, 1(3):1112-1116.
38. von Eckardstein K.L., Patt S., Kratzel C., Kiwit J.C., Reszka R. Local chemotherapy of F98 rat glioblastoma with paclitaxel and carboplatin embedded in liquid crystalline cubic phases. J Neurooncol 2005, 72(3):209-215.
39. +-ATPase inhibitor on cell and tumor response to camptothecins. J Pharmacol Exp Ther 2006, 318(3):939-946.
40. Sparreboom A., de Bruijn P., Nooter K., Loos W.J., Stoter G., Verweij J. Determination of paclitaxel in human plasma using single solvent extraction prior to isocratic reversed-phase high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl 1998, 705(1):159-164.
41. Kumar G.N., Walle U.K., Bhalla K.N., Walle T. Binding of taxol to human plasma, albumin and alpha 1-acid glycoprotein. Res Commun Chem Pathol Pharmacol 1993, 80(3):337-344.
42. Sonnichsen D.S., Relling M.V. Clinical pharmacokinetics of paclitaxel. Clin Pharmacokinet 1994, 27(4):256-269.
43. Xie Z., Guan H., Chen X., Lu C., Chen L., Hu X., et al. A novel polymer-paclitaxel conjugate based on amphiphilic triblock copolymer. J Control Release 2007, 117(2):210-216.
44. Chun C., Lee S.M., Kim S.Y., Yang H.K., Song S.C. Thermosensitive poly(organophosphazene)-paclitaxel conjugate gels for antitumor applications. Biomaterials 2009, 30(12):2349-2360.
45. Singer J.W. Paclitaxel poliglumex (XYOTAX, CT-2103): a macromolecular taxane. J Control Release 2005, 109(1-3):120-126.
46. Deutsch H.M., Glinski J.A., Hernandez M., Haugwitz R.D., Narayanan V.L., Suffness M., et al. Synthesis of congeners and prodrugs. 3. Water-soluble prodrugs of taxol with potent antitumor activity. J Med Chem 1989, 32(4):788-792.
47. Löscher W., Potschka H. Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx 2005, 2(1):86-98.
48. Groothuis D.R. The blood-brain and blood-tumor barriers: a review of strategies for increasing drug delivery. Neuro Oncol 2000, 2(1):45-59.